fbpx Skip to main content

WEDNESDAY, Oct. 7, 2020 (HealthDay News) — The overall prevalence of venous thromboembolism (VTE) in patients with COVID-19 is estimated to be 14.1 percent, with a higher prevalence for patients in the intensive care unit (ICU), according to a review published online Sep. 25 in Research and Practice in Thrombosis and Haemostasis.

Stephan Nopp, M.D., from the Medical University of Vienna, and colleagues conducted a systematic literature search to estimate the prevalence of VTE in patients with COVID-19. Data were identified from 86 studies with 33,970 patients; 66 studies with 28,173 patients were included in a quantitative analysis.

The researchers found that the overall prevalence estimate for VTE was 14.1 percent; the prevalence estimate was 40.3 percent with ultrasound screening and 9.5 percent without screening. High heterogeneity was seen in a subgroup analysis, with a VTE prevalence of 7.9 and 22.7 percent in non-ICU and ICU patients, respectively. The prevalence of pulmonary embolism was 3.5 and 13.7 percent in non-ICU and ICU patients, respectively. Higher D-dimer levels were seen in patients developing VTE versus non-VTE patients (weighted mean difference, 3.26 µg/mL).

“There is a clinical need for further research to better understand the risk and prevent VTE in patients with COVID-19,” the authors write. “These findings support the broad use of thromboprophylaxis, specifically in ICU patients.”

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Erythrocytosis ID'd in 11 Percent of Trans Men Using Testosterone

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More